Adherence to medical management of kidney stones: A systematic review.

UrolithiasisSep 28, 2026 (epub)
Clinical ResearchNephrologyOpen access

Bassel Salka, Rami Barqawi, Sarosh Irani et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated adherence to AUA guidelines for kidney stone management in adults, analyzing 35 studies with 57,970 patients. It found that greater adherence to preventive strategies correlates with fewer stone-related events, with fluid intake adherence at 65-85% and thiazide diuretics at 43-87%.

Key findings

  • Greater adherence to preventive strategies correlates with decreased stone-related events.
  • Fluid intake adherence ranged from 65-85%, the highest among lifestyle modifications.
  • Thiazide diuretics showed pharmacologic adherence of 43-87%, surpassing citrate therapy.
  • Predictors of improved adherence included older age and higher socioeconomic status.

Why it matters

Understanding adherence patterns to kidney stone prevention strategies is crucial for clinicians, as it directly impacts patient outcomes. Tailoring interventions based on patient characteristics can enhance adherence and reduce recurrence rates.

Source

PubMed · PMID 42803835Free full text on PubMed Central

Published in Urolithiasis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.